Praxis Precision Medicines, Inc. (PRAX)
| Market Cap | 7.87B +669.3% |
| Revenue (ttm) | n/a |
| Net Income | -339.13M |
| EPS | -12.86 |
| Shares Out | 27.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,989 |
| Open | 284.45 |
| Previous Close | 281.79 |
| Day's Range | 279.15 - 289.05 |
| 52-Week Range | 46.99 - 392.70 |
| Beta | 2.78 |
| Analysts | Strong Buy |
| Price Target | 638.68 (+126.6%) |
| Est. Earnings | Nov 4, 2026 |
About PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company’s platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in N... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price target is $638.68, which is an increase of 126.60% from the latest price.
News
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, t...
Praxis Precision price target raised to $575 from $470 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Praxis Precision (PRAX) to $575 from $470 and keeps a Buy rating on the shares.
Praxis Precision price target raised to $945 from $765 at Raymond James
Raymond James raised the firm’s price target on Praxis Precision (PRAX) to $945 from $765 and keeps a Strong Buy rating on the shares. Praxis has a compelling 6-12 month…
Praxis Precision price target raised to $462 from $449 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on Praxis Precision (PRAX) to $462 from $449 and keeps an Outperform rating on the shares. Praxis delivered important regulatory…
Praxis Precision price target raised to $514 from $400 at Baird
Baird raised the firm’s price target on Praxis Precision (PRAX) to $514 from $400 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
Praxis Precision price target raised to $362 from $323 at Wells Fargo
Wells Fargo analyst Benjamin Burnett raised the firm’s price target on Praxis Precision (PRAX) to $362 from $323 and keeps an Equal Weight rating on the shares. The firm is…
Praxis Precision Medicines Earnings Call Transcript: Q2 2026
Transitioning to commercial stage with two NDAs in late-stage FDA review, robust commercial infrastructure, and strong financial position. Regulatory milestones achieved, launches for ulixacaltamide and relutrigine expected in early 2027, and significant market opportunities identified.
Praxis Precision Medicines Earnings release: Q2 2026
Praxis Precision Medicines released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Praxis Precision Medicines Quarterly report: Q2 2026
Praxis Precision Medicines has published its Q2 2026 quarterly earnings report on August 6, 2026.
Praxis Precision Medicines Slides: Corporate presentation
Praxis Precision Medicines has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, to...
Praxis Precision initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Praxis Precision (PRAX) with a Buy rating and $447 price target Praxis is a clinical-stage biotech company with two potential drug approvals, ulixacaltamide in esse...
Praxis Precision, Remagine Labs announce research collaboration and license pact
Praxis Precision (PRAX) and Remagine Labs announced a research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide, Praxis’s highly sel...
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route Potential to expand the addressable market for ulixacaltamide beyond the initial patient popula...
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) pr...
Praxis Precision price target raised to $575 from $510 at Needham
Needham analyst Ami Fadia raised the firm’s price target on Praxis Precision (PRAX) to $575 from $510 and keeps a Buy rating on the shares. The firm is incrementally more…
Praxis Precision granted breakthrough therapy designation for elsunersen
Praxis Precision (PRAX) announced that the FDA has granted BTD for elsunersen, an antisense oligonucleotide for the treatment of seizures associated with SCN2A Developmental and Epileptic Encephalopat...
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen Elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizur...
Praxis Precision initiated with an Outperform at RBC Capital
RBC Capital analyst Leonid Timashev initiated coverage of Praxis Precision (PRAX) with an Outperform rating and $449 price target The firm believes think ulixacaltamide has a “reasonable likelihood” o...
Praxis Precision Medicines Transcript: AGM 2026
The meeting introduced board members and officers, confirmed a quorum, and presented three proposals: director elections, auditor ratification, and advisory executive compensation approval. All proposals passed with majority or plurality support.
Praxis Precision Medicines Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Essential tremor represents a large, underserved market, with ulixacaltamide positioned for a major launch and strong physician interest. The drug shows robust efficacy and safety, with commercial readiness and pricing strategies in place. Relutrigine and vormatrigine add to a promising pipeline.
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
BOSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, to...
Praxis Precision falls -15.4%
Praxis Precision (PRAX) is down -15.4%, or -$51.69 to $283.47.
Praxis Precision price target lowered to $616 from $715 at Truist
Truist lowered the firm’s price target on Praxis Precision (PRAX) to $616 from $715 and keeps a Buy rating on the shares. The firm is citing the company announcement that…
Praxis Precision price target lowered to $650 from $750 at Oppenheimer
Oppenheimer analyst Jay Olson lowered the firm’s price target on Praxis Precision (PRAX) to $650 from $750 and keeps an Outperform rating on the shares. The firm sees Monday’s announcement…